FBLN1 and breast carcinoma: One study shows that overexpression of FBLN-1 in breast cancer cell lines promotes resistance to doxorubicin [36], whereas another study reports that inhibition of FBLN-1 in cancer cell lines increases the sensitivity to the same drug [37].